Zacks Investment Research on MSN
Will Haemonetics (HAE) beat estimates again in its next earnings report?
Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report ...
Haemonetics (HAE) to acquire Vivasure Medical Limited for 100 million euros upfront plus potential milestone payments.
Currently priced at approximately $80.53 per share, Haemonetics (HAE) is trading roughly 7.6% below its 52-week ...
HAE affects about 1 in every 50,000 people in the U.S. This means there are fewer than 7,000 people in the country living with this disease. HAE is something you’re born with. But it can take time to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback